Physician profile
Wanda Choy
NPI 1730187352
$2,383.37
in general payments reported to CMS, 2019-2025
25 companies · $133 in 2025
The $133 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $304 · 2021: $546 · 2022: $750 · 2023: $27.47 · 2025: $133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $133 · Food and Beverage: $27.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $133.00 |
| Food and Beverage | $27.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $592.77 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $536.41 | 2019-2022 | |
| Insmed, INC. | $217.40 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.91 | 2019-2023 | Spiriva Respimat, Stiolto Respimat |
| Mylan Specialty L.P. | $142.96 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $99.00 | 2025 | |
| Pulmonx Corporation | $88.01 | 2019-2022 | |
| Genentech USA, INC. | $77.70 | 2019-2021 | |
| Genzyme Corporation | $63.08 | 2021-2022 | |
| Grifols USA, LLC | $60.48 | 2019-2022 | |
| Amgen INC. | $47.29 | 2022-2025 | |
| Philips North America LLC | $34.50 | 2022 | |
| Electromed, INC. | $33.61 | 2021 | |
| Pfizer INC. | $29.25 | 2022 | |
| Mallinckrodt Hospital Products INC. | $26.82 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $26.72 | 2020 | |
| Covis Pharma Gmbh | $26.69 | 2022 | |
| Circassia INC. | $25.20 | 2019 | |
| Sunovion Pharmaceuticals INC. | $24.46 | 2020 | |
| Harmony Biosciences LLC | $15.00 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $15.00 | 2020 | |
| Jazz Pharmaceuticals INC. | $14.17 | 2023 | Xywav |
| Regeneron Healthcare Solutions, INC. | $13.63 | 2021 | |
| Baxter Healthcare | $13.07 | 2022 | |
| Inogen, INC. | $6.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wanda Choy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.